As South Korea’s peptide market surges, partnership signals how AI is becoming active collaborator in search for medicines for healthy aging.
South Korea is one of the world’s most closely watched peptide markets. Demand is rising across therapeutics, biotechnology and even cosmetics, with the country’s therapeutic peptide market projected to reach $3.25 billion by 2033 [1].
For many Koreans, this reflects a national push to become a leader in next-generation healthcare – one where AI is beginning to help scientists imagine medicines that have never existed before. That ambition took another step forward this week as LG AI Research signed a definitive agreement with D&D Pharmatech to jointly develop AI-powered peptide therapeutics for hard-to-treat diseases and precision medicine [2].
From discovering molecules to designing them
In drug discovery, researchers sift through enormous numbers of possible molecules, hoping one will interact with a disease target in just the right way. It’s a process that often takes years before a promising candidate even reaches the laboratory. LG AI Research wants to compress that search.
Under the partnership, its AI models will analyze the structure of disease targets and generate peptide sequences that conventional approaches may never have identified. Rather than asking scientists to manually search for the right molecule, the AI proposes entirely new candidates based on patterns it has learned. It raises an intriguing possibility. AI may not replace scientific discovery, but it is beginning to reshape where discovery starts.
Just as architects now use software to explore hundreds of building designs before laying the first brick, researchers are increasingly using AI to explore vast chemical possibilities before carrying out experiments. The laboratory remains essential; AI simply helps narrow the search. Every molecule generated by LG’s models will still be synthesized, tested and validated by D&D Pharmatech before moving any further.
The rise of the AI co-scientist
This partnership also builds on a broader strategy unfolding inside LG AI Research. Beyond drug discovery, the company has developed EXAONE Discovery, an AI platform that allows researchers to interact with the system using natural language. Instead of spending days building computational models from scratch, scientists can ask questions, explore experimental ideas and predict outcomes through conversation.
The scientists still formulate the questions, challenge the results and decide which ideas deserve further investigation. However, AI is becoming an active participant in the research process rather than simply another piece of software running quietly in the background.
If the last decade introduced digital laboratories, the next may be defined by laboratories where human intuition and machine reasoning work side by side.
Can peptides finally leave the syringe behind?
One of the biggest hurdles facing peptide medicines has little to do with finding them; it’s getting them into the body.
Peptides are short chains of amino acids that can interact with biological processes with remarkable precision, making them attractive candidates for treating complex diseases. Yet they’re also fragile. Once swallowed, stomach acids and digestive enzymes often break them apart long before they can reach their target, leaving injections as the most reliable delivery method. That’s where D&D Pharmatech enters the picture.
While LG AI Research focuses on designing promising peptide candidates, D&D will develop oral peptide formulations alongside preclinical and clinical studies. Together, the companies hope to pair smarter molecular design with smarter delivery.
The companies also plan to establish a closed-loop development system in which laboratory results are continuously fed back into LG’s AI models. Each round of testing gives the system new information, allowing future designs to become increasingly refined.
If successful, that iterative process could shorten development timelines while improving the odds of finding candidates worthy of clinical trials.
Takeaways for longevity
Many of the diseases associated with aging, from metabolic disorders to neurodegenerative conditions, remain notoriously difficult to treat because discovering effective medicines is slow, expensive and uncertain. Anything that helps researchers explore more biological possibilities without compromising scientific rigor has the potential to accelerate progress.
Peptides are already emerging as an important class of therapeutics, and AI may help unlock applications that would otherwise remain hidden among billions of molecular combinations.
South Korea’s growing peptide economy signals a future in which AI becomes woven into every stage of medicine – from imagining new molecules to refining them in the lab and, ultimately, delivering them to patients.
As investment continues flowing into peptides, AI and precision medicine, the country’s expanding market may prove to be more than an economic success story. It could become an early glimpse of how longevity innovation is built: not by replacing scientists with algorithms, but by giving them better tools to solve some of aging’s most complex biological puzzles.
Photograph courtesy of LG AI Research. Main photograph shows LG AI Research Head Woohyung Lim and D&D Pharmatech CEO Seulki Lee at the definitive agreement signing ceremony.
[1] https://www.grandviewresearch.com/horizon/outlook/peptide-and-oligonucleotide-cdmo-market/south-korea
[2] https://www.lgresearch.ai/news/view?seq=657
